Cyclooxygenase-2 as a biomarker with diagnostic, therapeutic, prognostic, and predictive relevance in small animal oncology

1 Anadol E., Yar Saglam A.S., Gultiken N., Karakas K., Alcigir E., Alkan H., Kanca H.: Expression of iNOS, COX-2 and VEGF in canine mammary tumours and non-neoplastic mammary glands: association with clinicopathological features and tumour grade. Acta Vet Hung 2017, 65, 382–393. Anadol E. Yar Saglam A.S. Gultiken N. Karakas K. Alcigir E. Alkan H. Kanca H. Expression of iNOS, COX-2 and VEGF in canine mammary tumours and non-neoplastic mammary glands: association with clinicopathological features and tumour grade Acta Vet Hung 2017 65 382 39310.1556/004.2017.03628956485Search in Google Scholar

2 Araújo M.R., Campos L.C., Damasceno K.A., Gamba C.O., Ferreira E., Cassali G.D.: HER-2, EGFR, Cox-2, and Ki67 expression in lymph node metastasis of canine mammary carcinomas: association with clinical-pathological parameters and overall survival. Res Vet Sci 2016, 106, 121–130. Araújo M.R. Campos L.C. Damasceno K.A. Gamba C.O. Ferreira E. Cassali G.D. HER-2, EGFR, Cox-2, and Ki67 expression in lymph node metastasis of canine mammary carcinomas: association with clinical-pathological parameters and overall survival Res Vet Sci 2016 106 121 13010.1016/j.rvsc.2016.03.02027234549Search in Google Scholar

3 Arber N., Eagle C.J., Spicak J., Rácz I., Dite P., Hajer J., Zavoral M., Lechuga M.J., Gerletti P., Tang J., Rosenstein R.B., Macdonald K., Bhadra P., Fowler R., Wittes J., Zauber A.G., Solomon S.D., Levin B.: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355, 885–895. Arber N. Eagle C.J. Spicak J. Rácz I. Dite P. Hajer J. Zavoral M. Lechuga M.J. Gerletti P. Tang J. Rosenstein R.B. Macdonald K. Bhadra P. Fowler R. Wittes J. Zauber A.G. Solomon S.D. Levin B. Celecoxib for the prevention of colorectal adenomatous polyps N Engl J Med 2006 355 885 89510.1056/NEJMoa06165216943401Search in Google Scholar

4 Arenas C., Peña L., Granados-Soler J.L., Pérez-Alenza M.D.: Adjuvant therapy for highly malignant canine mammary tumours: Cox-2 inhibitor versus chemotherapy: a case-control prospective study. Vet Rec 2016, 179, 125. Arenas C. Peña L. Granados-Soler J.L. Pérez-Alenza M.D. Adjuvant therapy for highly malignant canine mammary tumours: Cox-2 inhibitor versus chemotherapy: a case-control prospective study Vet Rec 2016 179 12510.1136/vr.10339827377395Search in Google Scholar

5 Badowska-Kozakiewicz A.M.: Biological role of cyclooxygenase-2 in veterinary oncology. Życie Wet 2011, 86, 862–864. Badowska-Kozakiewicz A.M. Biological role of cyclooxygenase-2 in veterinary oncology Życie Wet 2011 86 862 864Search in Google Scholar

6 Bardagí M., Fondevila D., Ferrer L.: Immunohistochemical detection of COX-2 in feline and canine actinic keratoses and cutaneous squamous cell carcinoma. J Comp Pathol 2012, 146, 11–17. Bardagí M. Fondevila D. Ferrer L. Immunohistochemical detection of COX-2 in feline and canine actinic keratoses and cutaneous squamous cell carcinoma J Comp Pathol 2012 146 11 1710.1016/j.jcpa.2011.03.01221601872Search in Google Scholar

7 Beam S.L., Rassnick K.M., Moore A.S., McDonough S.P.: An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms. Vet Pathol 2003, 40, 496–500. Beam S.L. Rassnick K.M. Moore A.S. McDonough S.P. An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms Vet Pathol 2003 40 496 50010.1354/vp.40-5-49612949405Search in Google Scholar

8 Bommer N.X., Hayes A.M., Scase T.J., Gunn-Moore D.A.: Clinical features, survival times and COX-1 and COX-2 expression in cats with transitional cell carcinoma of the urinary bladder treated with meloxicam. J Feline Med Surg 2012, 14, 527–533. Bommer N.X. Hayes A.M. Scase T.J. Gunn-Moore D.A. Clinical features, survival times and COX-1 and COX-2 expression in cats with transitional cell carcinoma of the urinary bladder treated with meloxicam J Feline Med Surg 2012 14 527 53310.1177/1098612X1244204122408147Search in Google Scholar

9 Boria P.A., Murry D.J., Bennett P.F., Glickman N.W., Snyder P.W., Merkel B.L., Schlittler D.L., Mutsaers A.J., Thomas R.M., Knapp D.W.: Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2004, 224, 388–394. Boria P.A. Murry D.J. Bennett P.F. Glickman N.W. Snyder P.W. Merkel B.L. Schlittler D.L. Mutsaers A.J. Thomas R.M. Knapp D.W. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs J Am Vet Med Assoc 2004 224 388 39410.2460/javma.2004.224.38814765798Search in Google Scholar

10 Bronson R.T.: Variation in age at death of dogs of different sexes and breeds. Am J Vet Res 1982, 43, 2057–2059. Bronson R.T. Variation in age at death of dogs of different sexes and breeds Am J Vet Res 1982 43 2057 2059Search in Google Scholar

11 Carneiro C.S., de Queiroz G.F., Pinto A.C., Dagli M.L., Matera J.M.: Feline injection site sarcoma: immunohistochemical characteristics. J Feline Med Surg 2019, 21, 314–321. Carneiro C.S. de Queiroz G.F. Pinto A.C. Dagli M.L. Matera J.M. Feline injection site sarcoma: immunohistochemical characteristics J Feline Med Surg 2019 21 314 32110.1177/1098612X1877470929788832Search in Google Scholar

12 Carvalho M.I., Pires I., Prada J., Raposo T.P., Gregório H., Lobo L., Queiroga F.L.: High COX-2 expression is associated with increased angiogenesis, proliferation and tumoural inflammatory infiltrate in canine malignant mammary tumours: a multivariate survival study. Vet Comp Oncol 2017, 15, 619–631. Carvalho M.I. Pires I. Prada J. Raposo T.P. Gregório H. Lobo L. Queiroga F.L. High COX-2 expression is associated with increased angiogenesis, proliferation and tumoural inflammatory infiltrate in canine malignant mammary tumours: a multivariate survival study Vet Comp Oncol 2017 15 619 63110.1111/vco.1220626792550Search in Google Scholar

13 Carvalho S., Stoll A.L., Priestnall S.L., Suarez-Bonnet A., Rassnick K., Lynch S., Schoepper I., Romanelli G., Buracco P., Atherton M., de Merlo E.M., Lara-Garcia A.: Retrospective evaluation of COX-2 expression, histological and clinical factors as prognostic indicators in dogs with renal cell carcinomas undergoing nephrectomy. Vet Comp Oncol 2017, 15, 1280–1294. Carvalho S. Stoll A.L. Priestnall S.L. Suarez-Bonnet A. Rassnick K. Lynch S. Schoepper I. Romanelli G. Buracco P. Atherton M. de Merlo E.M. Lara-Garcia A. Retrospective evaluation of COX-2 expression, histological and clinical factors as prognostic indicators in dogs with renal cell carcinomas undergoing nephrectomy Vet Comp Oncol 2017 15 1280 129410.1111/vco.1226427578604Search in Google Scholar

14 Chandrasekharan N.V., Simmons D.L.: The cyclooxygenases. Genome Biol 2004, 5, 241. Chandrasekharan N.V. Simmons D.L. The cyclooxygenases Genome Biol 2004 5 24110.1186/gb-2004-5-9-24152286415345041Search in Google Scholar

15 De Campos C.B., Damasceno K.A., Gamba C.O., Ribeiro A.M., Machado C.J., Lavalle G.E., Cassali G.D.: Evaluation of prognostic factors and survival rates in malignant feline mammary gland neoplasms. J Feline Med Surg 2016, 18, 1003–1012. De Campos C.B. Damasceno K.A. Gamba C.O. Ribeiro A.M. Machado C.J. Lavalle G.E. Cassali G.D. Evaluation of prognostic factors and survival rates in malignant feline mammary gland neoplasms J Feline Med Surg 2016 18 1003 101210.1177/1098612X1561036726460079Search in Google Scholar

16 Dempke W., Rie C., Grothey A., Schmoll H.J.: Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 2001, 127, 411–417. Dempke W. Rie C. Grothey A. Schmoll H.J. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 2001 127 411 41710.1007/s00432000022511469677Search in Google Scholar

17 Denkert C., Winzer K.J., Muller B.M., Weichert W, Pest S., Kobel M., Kristiansen G., Reles A., Siegert A., Guski H., Hauptmann S.: Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003, 97, 2978–2987. Denkert C. Winzer K.J. Muller B.M. Weichert W Pest S. Kobel M. Kristiansen G. Reles A. Siegert A. Guski H. Hauptmann S. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma Cancer 2003 97 2978 298710.1002/cncr.1143712784332Search in Google Scholar

18 DiBernardi L., Doré M., Davis J.A., Owens J.G., Mohammed S.I., Guptill C.F., Knapp D.W.: Study of feline oral squamous cell carcinoma: potential target for cyclooxygenase inhibitor treatment. Prostaglandins Leukot Essent Fatty Acids 2007, 76, 245–250. DiBernardi L. Doré M. Davis J.A. Owens J.G. Mohammed S.I. Guptill C.F. Knapp D.W. Study of feline oral squamous cell carcinoma: potential target for cyclooxygenase inhibitor treatment Prostaglandins Leukot Essent Fatty Acids 2007 76 245 25010.1016/j.plefa.2007.01.00617383864Search in Google Scholar

19 Doré M.: Cyclooxygenase-2 expression in animal cancers. Vet Pathol 2011, 48, 254–265. Doré M. Cyclooxygenase-2 expression in animal cancers Vet Pathol 2011 48 254 26510.1177/030098581037943420876365Search in Google Scholar

20 Doré M., Lanthier I., Sirois J.: Cyclooxygenase-2 expression in canine mammary tumors. Vet Pathol 2003, 40, 207–212. Doré M. Lanthier I. Sirois J. Cyclooxygenase-2 expression in canine mammary tumors Vet Pathol 2003 40 207 21210.1354/vp.40-2-20712637762Search in Google Scholar

21 Gandhi J., Khera L., Gaur N., Paul C., Kaul R.: Role of modulator of inflammation cyclooxygenase-2 in gammaherpesvirus mediated tumorigenesis. Front Microbiol 2017, 8, 538. Gandhi J. Khera L. Gaur N. Paul C. Kaul R. Role of modulator of inflammation cyclooxygenase-2 in gammaherpesvirus mediated tumorigenesis Front Microbiol 2017 8 53810.3389/fmicb.2017.00538536827828400769Search in Google Scholar

22 Greenhough A., Smartt H.J.M., Moore A.E., Roberts H.R., Williams A.C., Paraskeva C., Kaidi A.: The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30, 377–386. Greenhough A. Smartt H.J.M. Moore A.E. Roberts H.R. Williams A.C. Paraskeva C. Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment Carcinogenesis 2009 30 377 38610.1093/carcin/bgp01419136477Search in Google Scholar

23 Gregório H., Raposo T., Queiroga F.L., Pires I., Pena L., Prada J.: High COX-2 expression in canine mast cell tumours is associated with proliferation, angiogenesis and decreased overall survival. Vet Comp Oncol 2017, 15, 1382–1392. Gregório H. Raposo T. Queiroga F.L. Pires I. Pena L. Prada J. High COX-2 expression in canine mast cell tumours is associated with proliferation, angiogenesis and decreased overall survival Vet Comp Oncol 2017 15 1382 139210.1111/vco.1228028467670Search in Google Scholar

24 Harris R.E.: Cyclooxygenase-2 (Cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacol 2009, 17, 55–67. Harris R.E. Cyclooxygenase-2 (Cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung Inflammopharmacol 2009 17 55 6710.1007/s10787-009-8049-819340409Search in Google Scholar

25 Heller D.A., Clifford C.A., Goldschmidt M.H., Holt D.E., Shofer A., Smith A., Sorenmo K.U.: Cyclooxygenase-2 expression is associated with histologic tumor type in canine mammary carcinoma. Vet Pathol 2005, 42, 776-780. Heller D.A. Clifford C.A. Goldschmidt M.H. Holt D.E. Shofer A. Smith A. Sorenmo K.U. Cyclooxygenase-2 expression is associated with histologic tumor type in canine mammary carcinoma Vet Pathol 2005 42 776 78010.1354/vp.42-6-77616301573Search in Google Scholar

26 Iturriaga M.P., Oaredes R., Arias J.I., Torres C.G.: Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells. Oncol Lett 2017, 14, 2198–2206. Iturriaga M.P. Oaredes R. Arias J.I. Torres C.G. Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells Oncol Lett 2017 14 2198 220610.3892/ol.2017.6400553018528781660Search in Google Scholar

27 Kandefer-Gola M., Nowak M., Dzimira S., Janus I., Ciaputa R., Madej J.A.: COX-2 and mPGES-1 expression in canine mast cell tumour. Med Weter 2015, 71, 345–348. Kandefer-Gola M. Nowak M. Dzimira S. Janus I. Ciaputa R. Madej J.A. COX-2 and mPGES-1 expression in canine mast cell tumour Med Weter 2015 71 345 34810.1016/j.jcpa.2014.10.101Search in Google Scholar

28 Kankuri-Tammilehto M.K., Soderstrom K.O., Pelliniemi T.T., Vahlberg T., Pyrhonen S.O., Salminen E.K.: Prognostic evaluation of COX-2 expression in renal cell carcinoma. Anticancer Res 2010, 30, 3023–3030. Kankuri-Tammilehto M.K. Soderstrom K.O. Pelliniemi T.T. Vahlberg T. Pyrhonen S.O. Salminen E.K. Prognostic evaluation of COX-2 expression in renal cell carcinoma Anticancer Res 2010 30 3023 3030Search in Google Scholar

29 Kardosh A., Wang W., Uddin J., Petasis N.A., Hofman F.M., Chen T.C., Schonthal A.H.: Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt’s lymphoma in vitro and in vivo Cancer Biol Ther 2005, 4, 571–582. Kardosh A. Wang W. Uddin J. Petasis N.A. Hofman F.M. Chen T.C. Schonthal A.H. Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt’s lymphoma in vitro and in vivo Cancer Biol Ther 2005 4 571 58210.4161/cbt.4.5.169915846081Search in Google Scholar

30 Khuri F.R., Wu H., Lee J.J., Kemp B.L., Lotan R., Lippman S.M., Feng L., Hong W.K., Xu X.C.: Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001, 7, 861–867. Khuri F.R. Wu H. Lee J.J. Kemp B.L. Lotan R. Lippman S.M. Feng L. Hong W.K. Xu X.C. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer Clin Cancer Res 2001 7 861 867Search in Google Scholar

31 King J.N., Arnaud J.P., Goldenthal E.I., Gruet P., Jung M., Seewald W., Lees P.: Robenacoxib in the dog: target species safety in relation to extent and duration of inhibition of COX-1 and COX-2. J Vet Pharmacol Ther 2011, 34, 298–311. King J.N. Arnaud J.P. Goldenthal E.I. Gruet P. Jung M. Seewald W. Lees P. Robenacoxib in the dog: target species safety in relation to extent and duration of inhibition of COX-1 and COX-2 J Vet Pharmacol Ther 2011 34 298 31110.1111/j.1365-2885.2010.01209.x21492194Search in Google Scholar

32 King J.N., Hotz R., Reagan E.L., Roth D.R., Seewald W., Lees P.: Safety of oral robenacoxib in the cat. J Vet Pharmacol Ther 2012, 35, 290–300. King J.N. Hotz R. Reagan E.L. Roth D.R. Seewald W. Lees P. Safety of oral robenacoxib in the cat J Vet Pharmacol Ther 2012 35 290 30010.1111/j.1365-2885.2011.01320.x21736587Search in Google Scholar

33 Knapp D.W., Glickman N.W., Widmer W.R., DeNicola D.B., Adams L.G., Kuczek T., Bonney P.L., DeGortari A.E., Han C., Glickman L.T.: Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 2000, 46, 221–226. Knapp D.W. Glickman N.W. Widmer W.R. DeNicola D.B. Adams L.G. Kuczek T. Bonney P.L. DeGortari A.E. Han C. Glickman L.T. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer Cancer Chemother Pharmacol 2000 46 221 22610.1007/s00280000014711021739Search in Google Scholar

34 Liao Z., Milas L., Komaki R., Stevens C., Cox J.D.: Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer. Am J Clin Oncol 2003, 26, 85–91. Liao Z. Milas L. Komaki R. Stevens C. Cox J.D. Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer Am J Clin Oncol 2003 26 85 9110.1097/01.COC.0000074307.55019.2912902863Search in Google Scholar

35 Magi G.E., Mari S., Renzoni G., Rossi G.: Immunohistochemical expression of COX-2 in feline injection site sarcoma. Vet Pathol 2010, 4, 340. Magi G.E. Mari S. Renzoni G. Rossi G. Immunohistochemical expression of COX-2 in feline injection site sarcoma Vet Pathol 2010 4 34010.1016/j.jcpa.2010.09.110Search in Google Scholar

36 Mehta S., Shelling A., Muthukaruppan A., Lasham A., Blenkiron C., Laking G., Print C.: Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol 2010, 2, 125–148. Mehta S. Shelling A. Muthukaruppan A. Lasham A. Blenkiron C. Laking G. Print C. Predictive and prognostic molecular markers for cancer medicine Ther Adv Med Oncol 2010 2 125 14810.1177/1758834009360519312601121789130Search in Google Scholar

37 Millanta F., Andreani G., Rocchigiani G., Lorenzi D., Poli A.: Correlation between cyclo-oxygenase-2 and vascular endothelial growth factor expression in canine and feline squamous cell carcinomas. J Comp Pathol 2016, 154, 297–303. Millanta F. Andreani G. Rocchigiani G. Lorenzi D. Poli A. Correlation between cyclo-oxygenase-2 and vascular endothelial growth factor expression in canine and feline squamous cell carcinomas J Comp Pathol 2016 154 297 30310.1016/j.jcpa.2016.02.00527012907Search in Google Scholar

38 Millanta F., Asproni P., Canale A., Citi S., Poli A.: COX-2, mPGES-1 and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumours. Vet Comp Oncol 2016, 14, 270–280. Millanta F. Asproni P. Canale A. Citi S. Poli A. COX-2, mPGES-1 and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumours Vet Comp Oncol 2016 14 270 28010.1111/vco.1209624824420Search in Google Scholar

39 Millanta F., Citi S., Della Santa D., Porciani M., Poli A.: COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic molecular markers. Breast Cancer Res Treat 2006, 98, 115–120. Millanta F. Citi S. Della Santa D. Porciani M. Poli A. COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic molecular markers Breast Cancer Res Treat 2006 98 115 12010.1007/s10549-005-9138-z16538539Search in Google Scholar

40 Mohammed S.I., Bennett P.F., Craig B.A., Glickman N.W., Mutsaers A.J., Snyder P.W., Widmer W.R., DeGortari A.E., Bonney P.L., Knapp D.W.: Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002, 62, 356–358. Mohammed S.I. Bennett P.F. Craig B.A. Glickman N.W. Mutsaers A.J. Snyder P.W. Widmer W.R. DeGortari A.E. Bonney P.L. Knapp D.W. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer Cancer Res 2002 62 356 358Search in Google Scholar

41 Mohammed S.I., Khan K.N., Sellers R.S., Hayek M.G., DeNicola D.B., Wu L., Bonney P.L., Knapp D.W.: Expression of cyclooxygenase-1 and 2 in naturally-occurring canine cancer. Prostaglandins Leukot Essent Fatty Acids 2004, 70, 479–483. Mohammed S.I. Khan K.N. Sellers R.S. Hayek M.G. DeNicola D.B. Wu L. Bonney P.L. Knapp D.W. Expression of cyclooxygenase-1 and 2 in naturally-occurring canine cancer Prostaglandins Leukot Essent Fatty Acids 2004 70 479 48310.1016/j.plefa.2003.10.00215062852Search in Google Scholar

42 Nasry W.H.S., Jones K., Dirksen W.P., Rosol T.J., Rodriguez-Lecompte J.C., Martin C.K.: CD147 and cyclooxygenase expression in feline oral squamous cell carcinoma. Vet Sci 2018, 5, 72. Nasry W.H.S. Jones K. Dirksen W.P. Rosol T.J. Rodriguez-Lecompte J.C. Martin C.K. CD147 and cyclooxygenase expression in feline oral squamous cell carcinoma Vet Sci 2018 5 7210.3390/vetsci5030072616361130104530Search in Google Scholar

43 Nóbrega D.F., Sehaber V.F., Madureira R., Bracarense A.P.F.R.L.: Canine cutaneous haemangiosarcoma: biomarkers and survival. J Comp Pathol 2019, 166, 87–96. Nóbrega D.F. Sehaber V.F. Madureira R. Bracarense A.P.F.R.L. Canine cutaneous haemangiosarcoma: biomarkers and survival J Comp Pathol 2019 166 87 9610.1016/j.jcpa.2018.10.18130691610Search in Google Scholar

44 Nowak M., Madej J.A., Dzięgiel P.: Immunohistochemical localization of COX-2 in cells of mammary adenocarcinomas in bitches as related to tumour malignancy grade. Bull Vet Inst Pulawy 2005, 49, 433–437. Nowak M. Madej J.A. Dzięgiel P. Immunohistochemical localization of COX-2 in cells of mammary adenocarcinomas in bitches as related to tumour malignancy grade Bull Vet Inst Pulawy 2005 49 433 437Search in Google Scholar

45 Pang L.Y., Argyle S.A., Kamida A., O’Neill Morrison K., Argyle D.: The long-acting COX-2 inhibitor mavacoxib (Trocoxil^TM has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro BMC Vet Res 2014, 10, 465. Pang L.Y. Argyle S.A. Kamida A. O’Neill Morrison K. Argyle D. The long-acting COX-2 inhibitor mavacoxib (Trocoxil^TM has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro BMC Vet Res 2014 10 46510.1186/s12917-014-0184-9417295825190452Search in Google Scholar

46 Pestili de Almeida E.M., Piché C., Sirois J., Doré M.: Expression of cyclooxygenase-2 in naturally occurring squamous cell carcinomas in dogs. J Histochem Cytochem 2001, 49, 867–875. Pestili de Almeida E.M. Piché C. Sirois J. Doré M. Expression of cyclooxygenase-2 in naturally occurring squamous cell carcinomas in dogs J Histochem Cytochem 2001 49 867 87510.1177/00221554010490070711410611Search in Google Scholar

47 Queiroga F.L., Perez-Alenza M.D., Silvan G., Pena L., Lopes C., Illera J.C.: Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance. Anticancer Res 2005, 25, 4269–4276. Queiroga F.L. Perez-Alenza M.D. Silvan G. Pena L. Lopes C. Illera J.C. Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance Anticancer Res 2005 25 4269 4276Search in Google Scholar

48 Queiroga F.L., Pires I., Lobo L., Lopes C.S.: The role of Cox-2 expression in the prognosis of dogs with malignant mammary tumours. Res Vet Sci 2010, 88, 441–445. Queiroga F.L. Pires I. Lobo L. Lopes C.S. The role of Cox-2 expression in the prognosis of dogs with malignant mammary tumours Res Vet Sci 2010 88 441 44510.1016/j.rvsc.2009.10.00919939424Search in Google Scholar

49 Ring B.Z., Seitz R.S., Beck R., Shasteen W.J., Tarr S.M., Cheang M.C., Yoder B.J., Budd G.T., Nielsen T.O., Hicks D.G., Estopinal N.C., Ross D.T.: Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24, 3039–3047. Ring B.Z. Seitz R.S. Beck R. Shasteen W.J. Tarr S.M. Cheang M.C. Yoder B.J. Budd G.T. Nielsen T.O. Hicks D.G. Estopinal N.C. Ross D.T. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer J Clin Oncol 2006 24 3039 304710.1200/JCO.2006.05.656416809728Search in Google Scholar

50 Rizzo M.T.: Cyclooxygenase-2 in oncogenesis. Clin Chem Acta 2011, 412, 671–687. Rizzo M.T. Cyclooxygenase-2 in oncogenesis Clin Chem Acta 2011 412 671 68710.1016/j.cca.2010.12.02621187081Search in Google Scholar

51 Samarini F., de la Fuente C., Parodi A., Mandara M.T., Pumarola M., Anor S.: Immunohistochemical expression of cyclooxygenase-2 (COX-2) is not associated with tumor grade in feline meningiomas. Vet J 2018, 241, 20–23. Samarini F. de la Fuente C. Parodi A. Mandara M.T. Pumarola M. Anor S. Immunohistochemical expression of cyclooxygenase-2 (COX-2) is not associated with tumor grade in feline meningiomas Vet J 2018 241 20 2310.1016/j.tvjl.2018.09.00930340655Search in Google Scholar

52 Santelices Iglesias O.A., Wright C., Duchene A.G., Risso M.A., Risso P., Zanuzzi C.N., Nishida F., Lavid A., Confente F., Díaz M., Portiansky E.L., Gimeno E.J., Barbeito C.G.: Association between degree of anaplasia and degree of inflammation with the expression of COX-2 in feline injection site sarcomas. J Comp Pathol 2018, 165, 45–51. Santelices Iglesias O.A. Wright C. Duchene A.G. Risso M.A. Risso P. Zanuzzi C.N. Nishida F. Lavid A. Confente F. Díaz M. Portiansky E.L. Gimeno E.J. Barbeito C.G. Association between degree of anaplasia and degree of inflammation with the expression of COX-2 in feline injection site sarcomas J Comp Pathol 2018 165 45 5110.1016/j.jcpa.2018.09.00230502795Search in Google Scholar

53 Sayasith K., Sirois J., Doré M.: Molecular characterization of feline COX-2 and expression in feline mammary carcinomas. Vet Pathol 2009, 46, 423–429. Sayasith K. Sirois J. Doré M. Molecular characterization of feline COX-2 and expression in feline mammary carcinomas Vet Pathol 2009 46 423 42910.1354/vp.08-VP-0161-D-FL19176489Search in Google Scholar

54 Schmidt B.R., Glickman N.W., DeNicola D.B., de Gortari A.E., Knapp D.W.: Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2001, 218, 1783–1786. Schmidt B.R. Glickman N.W. DeNicola D.B. de Gortari A.E. Knapp D.W. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs J Am Vet Med Assoc 2001 218 1783 178610.2460/javma.2001.218.178311394830Search in Google Scholar

55 Sorenmo K.U., Goldschmidt M., Shofer F.S., Goldkamp C., Ferracone J.: Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. Vet Comp Oncol 2004, 2, 13–23. Sorenmo K.U. Goldschmidt M. Shofer F.S. Goldkamp C. Ferracone J. Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma Vet Comp Oncol 2004 2 13 2310.1111/j.1476-5810.2004.00035.x19379307Search in Google Scholar

56 Sparger E.E., Murphy B.G., Kamal F.M., Arzi B., Naydan D., Skouritakis C.T., Cox D.P., Skorupski K.: Investigation of immune cell markers in feline oral squamous cell carcinoma. Vet Immunol Immunopathol. 2018, 202, 52–62. Sparger E.E. Murphy B.G. Kamal F.M. Arzi B. Naydan D. Skouritakis C.T. Cox D.P. Skorupski K. Investigation of immune cell markers in feline oral squamous cell carcinoma Vet Immunol Immunopathol 2018 202 52 6210.1016/j.vetimm.2018.06.011648484830078599Search in Google Scholar

57 Szweda M., Rychlik A., Babińska I., Pomianowski A.: The significance of cyclooxygenase-2 in oncogenesis. J Vet Res 2019, 63, 215–224. Szweda M. Rychlik A. Babińska I. Pomianowski A. The significance of cyclooxygenase-2 in oncogenesis J Vet Res 2019 63 215 22410.2478/jvetres-2019-0030659818431276061Search in Google Scholar

58 Tamura D., Saito T., Murata K., Kawashima M., Asano R.: Celecoxib exerts antitumor effects in canine mammary tumor cells via COX-2-independent mechanisms. Int J Oncol 2015, 46, 1393–404. Tamura D. Saito T. Murata K. Kawashima M. Asano R. Celecoxib exerts antitumor effects in canine mammary tumor cells via COX-2-independent mechanisms Int J Oncol 2015 46 1393 40410.3892/ijo.2015.282025571853Search in Google Scholar

59 Veer van ’t L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415, 530–536. Veer van ’t L.J. Dai H. van de Vijver M.J. He Y.D. Hart A.A. Mao M. Peterse H.L. van der Kooy K. Marton M.J. Witteveen A.T. Schreiber G.J. Kerkhoven R.M. Roberts C. Linsley P.S. Bernards R. Friend S.H. Gene expression profiling predicts clinical outcome of breast cancer Nature 2002 415 530 53610.1038/415530a11823860Search in Google Scholar

60 Withrow S.J., MacEwen E.G.: Small Animal Clinical Oncology, 6^th ed., edited by D. Vail, D. Thamm, J. Liptak, Saunders, 2019. Withrow S.J. MacEwen E.G. Small Animal Clinical Oncology 6^th ed., edited by VailD. ThammD. LiptakJ. Saunders 2019Search in Google Scholar